Register here and get a free copy of the Syngene-Baxter case study

Key discussion points:

COVID-19 is affecting us all in a way none of us could have imagined possible just a month ago. Work from home, social distancing and being in quarantine seem to be the new normal. Every company and individual is struggling to adapt to this reality.
 
In such a scenario,  enabling collaboration and unfettered exchange of ideas becomes all the more important. With that thought in mind,  we decided to launch this Live-Chat series. The chat involves a 45 minutes discussion on topics that are of importance to scientists and the scientific community at large, to help them move forward in these difficult times.

About Syngene's Live-Chat series

Syngene reserves the right, at its discretion, to change, modify, add, or remove participation.

  • Lessons from a decade-long Stability CoE collaboration: The Syngene-Baxter R&D Centre

  • Pointers for moving from Capex to fully Opex model

  • Analytical capabilities and technical problem-solving skills as a measure of delivery excellence in ICH stability

  • Leveraging digital platforms for effective management of compliance challenges

  • Maintaining business continuity during a pandemic: A Syngene case study

© Syngene International Ltd.
Syngene International Ltd. Biocon Park, SEZ, Bommasandra Industrial Area - Phase - IV, Bangalore 560099 India

Host: Ashu Tandon | Chief Commercial Officer, Syngene

Ashu has 20 years experience in the global biopharmaceuticals industry which includes Sales and Account Management leadership across consulting, and outsourcing services in Research & Development. He has a successful track record of building multi-million dollar deals across multiple industry verticals and geographies.

As a member of Syngene's Executive Committee, he plays an important role in driving strategy related to Commercial activities. Prior to joining Syngene, Ashu was with IQVIA (formerly QuintilesIMS), Infosys and Accenture.

Panelist: Chetan Tamhankar | VP & Head - Clinical Development & Stability Services, Syngene

Chetan holds a Ph.D in Bio-pharmaceuticals and a Masters in Pharmacology from Mumbai University. He has more than 19 years of experience in life-sciences business spanning across CRO and healthcare sectors. He has played an active role in healthcare startups and held senior management roles in other leading CROs.

Prior to joining Syngene in 2016, Chetan was associated with SIRO Clinpharm.

Panelist: Dr. Shreekant Karmarkar | President, DAT Pharma Consulting

Dr. Shreekant Karmarkar has around 30 years of academic and industrial experience in analytical chemistry. He has developed analytical instruments and methodologies to solve industrial challenges. He has also led analytical development for Baxter’s pharmaceutical drug products right from feasibility studies, validations, transfers, regulatory submission and commercial launch, to complete life cycle management of the drug product.

Dr. Shreekant successfully led Baxter's strategic partnership with Syngene consisting of around 200 FTEs working on product sustenance and analytical work for new drug products. The collaboration turned out to be one of the best collaborations within Baxter through implementation of several key strategies. The strategies ranged from simplifying the complex, building trust, empowerment, engagement, governance and continuous improvement to Key Performance Indicators (KPIs).